Pluri Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $17.2M
- Price
- $1.71
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.39%
- Volume
- 4.6K
About
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Quick stats
Shares outstanding10.1M
Computed float6.1M
Float / shares60.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001158780
Websitehttps://pluri-biotech.com
AI Summary
AI-generated1/22
majorbullishm and a
Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment
Pluri's majority-owned subsidiary, Ever After Foods, acquired Fishway BV, a Belgium-based biotechnology company specializing in aquatic cell biology and animal-component-free media, to expand its cultivated-protein platform.
The transaction is supported by a $2 million strategic investment through a SAFE Agreement, intended to fund ongoing platform development and commercialization activities.
Management expects the acquisition to bolster EAF's European footprint and enhance its ability to support food and ingredient clients in scaling production.